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Background: Pathogenic variants in the Leucine-rich repeat kinase 2 (LRRK2) gene are
the most common known monogenic cause of Parkinson’s disease (PD). LRRK2-linked
PD is clinically indistinguishable from idiopathic PD and inherited in an autosomal
dominant fashion with reduced penetrance and variable expressivity that differ across
ethnicities and geographic regions.
Objective: To systematically assess clinical signs and symptoms including non-motor
features, comorbidities, medication and environmental factors in PD patients, unaffected
LRRK2 pathogenic variant carriers, and controls. A further focus is to enable the
investigation of modifiers of penetrance and expressivity of LRRK2 pathogenic variants
using genetic and environmental data.
Methods: Eligible participants are invited for a personal or online examination which
comprises completion of a detailed eCRF and collection of blood samples (to obtain
DNA, RNA, serum/plasma, immune cells), urine as well as household dust. We plan to
enroll 1,000 participants internationally: 300 with LRRK2-linked PD, 200 with LRRK2
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pathogenic variants but without PD, 100 PD patients with pathogenic variants in the
GBA or PRKN genes, 200 patients with idiopathic PD, and 200 healthy persons without
pathogenic variants.
Results: The eCRF consists of an investigator-rated (1 h) and a self-rated (1.5 h) part.
The first part includes theMovement Disorder Society Unified Parkinson’s Disease Rating,
Hoehn &Yahr, and Schwab & England Scales, the Brief Smell Identification Test, and
Montreal Cognitive Assessment. The self-rating part consists of a PD risk factor, food
frequency, autonomic dysfunction, and quality of life questionnaires, the Pittsburgh Sleep
Quality Inventory, and the Epworth Sleepiness as well as the Hospital Anxiety and
Depression Scales. The first 15 centers have been initiated and the first 150 participants
enrolled (as of March 25th, 2021).
Conclusions: LIPAD is a large-scale international scientific effort focusing on deep
phenotyping of LRRK2-linked PD and healthy pathogenic variant carriers, including
the comparison with additional relatively frequent genetic forms of PD, with a
future perspective to identify genetic and environmental modifiers of penetrance
and expressivity
Clinical Trial Registration: ClinicalTrials.gov, NCT04214509.
Keywords: Parkinson’s disease, LRRK2, GBA, clinical study, genetic cohort
INTRODUCTION
Pathogenic variants in the Leucine-rich repeat kinase 2 (LRRK2)
gene are the most common known monogenic cause of
Parkinson’s disease (PD). First identified in 2004, LRRK2
pathogenic variants account for up to ∼40% of all PD cases in
selected populations, e.g., North African Berber (1). In the PD
phenotype-genotype database MDSGene (www.mdsgene.org),
∼700 individual LRRK2 pathogenic variant carriers are listed, but
clinical information apart from cardinal signs of PD is overall
scarce (1).
The majority of the reported LRRK2 pathogenic variant-
positive PD patients are of European descent (63%), whereas all
other ethnicities comprise ∼10% or fewer patients of described
pathogenic variant carriers despite clusters in the Ashkenazi
Jewish (AJ) and Arab Berber populations (1, 2). Definitely
pathogenic variants identified in LRRK2 include p.G2019S,
p.R1441C/G/H, p.N1437H, p.Y1699C, and, p.I2020T. Of these,
the p.G2019S pathogenic variant is the most common with an
estimated frequency of 1% in sporadic and 4% in hereditary PD
cases worldwide (3). However, data on many populations are
still missing.
LRRK2-linked PD is inherited in an autosomal dominant
fashion with reduced, age-dependent penetrance and variable
expressivity that differ across ethnicities and geographic regions,
indicating that ancestral background or environmental factors
contribute to the manifestation and expressivity of pathogenic
LRRK2 variants. For example, at the age of 60 years, 60% of
Tunisian p.G2019S pathogenic variant carriers manifest PD,
compared with only 20% of the Norwegian carriers of the
same pathogenic variant (4). Recent studies have suggested
mitochondrial involvement in the penetrance of LRRK2-linked
PD (5, 6). Environmental factors can also influence penetrance,
as recently found in the Tunisian Arab Berber population,
where tobacco and black tea use delayed age at onset in LRRK2
pathogenic variant carriers (7).
LRRK2-linked PD is clinically indistinguishable from
idiopathic PD, i.e., PD of unknown cause, although the disease
course appears to be milder with regard to motor and cognitive
functions (8). In this comparatively small subgroup of PD
patients with a known etiology, valuable clues can be garnered
toward pathophysiological mechanisms and targeted treatments,
which may be generalized to idiopathic PD. Currently, there are
three substances in clinical trial specifically targeting LRRK2: the
LRRK2 kinase inhibitors DNL151 (NCT04557800) and DNL201
(NCT04551534) from Denali and the antisense oligonucleotide
BIIB094 (NCT03976349) from Biogen (2). However, no genetic
testing guidelines and no clinical trial-ready cohorts exist to date.
To identify LRRK2 pathogenic variant carriers among 10,000
PD patients from 15 countries and to establish a clinical trial-
ready cohort, the ROPAD study was initiated (9). The ROPAD
study performs genetic testing of pathogenic variants in the
LRRK2 and GBA genes and, if negative, carries out genetic
screening of 68 genes linked to PD or related movement
disorders. Out of the first 1,288 participants who underwent
genetic testing in ROPAD, 40 (3.1%) harbored pathogenic or
likely pathogenic LRRK2 variants, 109 (8.5%) harbored GBA
variants, three (0.2%) had alterations in both genes (9). The
ROPAD study is still ongoing and continues to identify LRRK2
pathogenic variant carriers internationally. It gathers only basic
clinical data: age at examination, age at onset, cardinal PD
symptoms, and 12/33 items of MDS-UPDRS Part III and, thus,
does not allow a systematic in-depth characterization of LRRK2
pathogenic variant carriers.
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FIGURE 1 | Paths of enrolment into the LIPAD study. LRRK2+/PD+: PD patients carrying a pathogenic LRRK2 variant, LRRK2+/PD-: unaffected carriers of
pathogenic LRRK2 variants, genPD: PD patients with pathogenic variants in PD genes other than LRRK2, iPD; LRRK2-/PD+: patients with idiopathic PD from the
same populations, HC: healthy persons without pathogenic variants.
Recently published data from the currently largest
multinational prospective study that includes LRRK2 pathogenic
variant carriers, i.e., the Parkinson’s Progression Markers
Initiative (PPMI), provide more phenotypic details on LRRK2
pathogenic variant carriers across international sites (6).
However, as the focus of the PPMI study is predominantly on
biomarkers, it does not cover environmental factors in-depth,
and only includes participants with a PD diagnosis 2 years or
less before enrolment who are untreated with PD medication.
There remains a gap in combining phenotypic, genetic, and
environmental data on LRRK2 pathogenic variant carriers
internationally, regardless of the onset of signs and symptoms
and their medication status, that LIPAD is aiming to close. The
objectives of the LIPAD study are (1) to provide a systematic
characterization of PD patients and unaffected carriers with
pathogenic variants in the LRRK2 gene; and (2) to enable the
investigation of modifiers of penetrance of LRRK2 pathogenic
variants using genetic and environmental data.
Here, we describe a protocol and a feasibility study of the first
150 participants and give a brief overview of nested studies within
LIPAD.Of note, the LIPADprotocol has also been adapted to take
place online due to COVID19 contact restriction measures.
PATIENTS AND METHODS
General Setting
We aim to build the LIPAD cohort consisting of 1,000
participants internationally: 300 of them with LRRK2-PD
(LRRK2+/PD+), 200 with pathogenic LRRK2 variants but
without PD (LRRK2+/PD-), 100 PD patients with pathogenic
variants in PD genes other than LRRK2 (genPD), 200 patients
with idiopathic PD from the same populations (iPD; LRRK2-
/PD+), and 200 healthy persons without pathogenic variants
(HC). The majority of participants will be enrolled after genetic
analysis within ROPAD (Figure 1). Extrapolating from the
ROPAD findings, we expect to have a sufficient number of
participants in the LRRK2+/ PD+, iPD, and genPD groups.
Further, family members of pathogenic LRRK2 variant carriers
will be asked to participate in the LIPAD study and will be
genetically tested for the familial pathogenic LRRK2 variant.
Depending on the results, they will be assigned either to
LRRK2+/PD- or HC group. Healthy persons without pathogenic
variants will be recruited from spouses of study participants
or the general population. Within an anticipated 24-month
recruitment period per site, ∼25 centers in 10 countries on three
continents will be established. Each center will have 24 months
for recruitment after initiation. The majority of the centers will
be those already participating in ROPAD, however, additional
centers that do not participate in ROPAD but follow LRRK2
pathogenic variant carriers will be invited to become LIPAD sites.
Inclusion Criteria
Recruited participants have to meet one of the following criteria:
(i) clinical diagnosis of PD according to the Movement disorder
Society (MDS) diagnostic criteria, (ii) first- or second-degree
relative of a participant that is positive for a pathogenetic LRRK2
variant, (iii) healthy participants with or without a family history
of PD in a control group. All participants have to be above 18
years of age and have to sign an informed consent form.
Participants with the following LRRK2 variants will be
included in the LRRK2+ group: p.Gly2019Ser (c.6055G>A),
p.Arg1441His (c.4322G>A), p.Arg1441Cys (c.4321C>T),
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p.Arg1441Gly (c.4321C>G), p.Asn1437His (c.4309A>C),
p.Ile2020Thr (c.6059T>C), p.Tyr1699Cys (c.5096A>G).
Study Design
Upon completion of genetic screening (e.g., in ROPAD),
participants are invited for a personal examination using
the three-level biomaterial protocol. During a single visit, an
electronic Case Report Form (eCRF) is administered and blood
samples for DNA, RNA, serum/plasma, immune cell isolation,
urine, and household dust for toxicological analyses are collected.
The three-level protocol was designed to accommodate
available laboratory facilities at the different sites. The details of
the three levels for biomaterial sampling are listed in Supporting
Information Methods S2 in Supplementary Material.
In case genetic testing has not been performed before, a dried
blood spot card will be sent for DNA extraction and genetic
screening, as specified in ROPAD.
There are no serious safety concerns associated with the
study. Participants may experience temporary discomfort during
venous blood sampling and while answering the questions.
However, they are instructed that they are free to omit questions
they would rather not answer. There are no health risks
associated with the collection of urine and house dust.
Data Analysis
Data analysis will be performed at the Institute of Neurogenetics
(University of Luebeck, Germany). To cover the first objective,
which is the systematic characterization of PD patients and
unaffected carriers with pathogenic variants in the LRRK2 gene,
we will describe the frequency of all clinical signs and symptoms
including non-motor signs and the most important influencing
factors such as sex, disease duration, and medication. This will
result in raw and corrected frequencies with 95% confidence
intervals. We will use t-tests for numerical and continuous
variables and chi-square tests for categorical variables at a
significance level of 0.05 for the comparisons of the clinical signs
and symptoms across the groups.
For aim 2, which is to investigate the modifiers of penetrance
of pathogenic LRRK2 variants using genetic and environmental
data, we will examine penetrance in logistic regression models to
quantify the influence of different factors impacting penetrance.
Nested Studies
All LIPAD centers can suggest nested projects, which will be
coordinated by a Scientific Advisory Board. These projects
can apply for external funding, will have individual ethics
approvals, and can use the ROPAD/LIPAD network. The
following nested studies are planned or have started at the
Institute of Neurogenetics (University of Luebeck):
Multimodal High-Quality Magnetic Resonance
Imaging (MRI)
Penetrance of LRRK2-linked PD depends on the age of a given
individual subject. Asymptomatic carriers may, however, already
demonstrate neurodegenerative changes including hyposmia,
abnormal midbrain hyperechogenicity upon transcranial
sonography, pathologic dopaminergic neurotransmission,
structural changes of the gray and white matter, and functional
reorganization of neural networks. Although first morphological
and functional brain changes in pathogenic LRRK2 variant
carriers have already been identified, the overall picture is
still elusive due to the relatively low number of included
subjects in most studies, ascertainment biases, and variable
imaging protocols. Multimodal high-quality MRI, however, is a
promising secondary endpoint for clinical trials given its wide
availability, cost-effectiveness, and lack of radiation.
To reveal an MRI-based biomarker for LRRK2+/PD+ and
prodromal LRRK2+/PD+, we aim to acquire the following
MRI modalities:
1. Multiparameter mapping (R1, PD∗, MT, and R2∗) to reveal
physical tissue properties.
2. Diffusion-weighted imaging for multicompartment
diffusion models to reveal neuroinflammation and
microstructural alterations.
3. Neuromelanin imaging to reveal substantia nigra and locus
coeruleus degeneration.
4. Blood-oxygen-level-dependent functional MRI to identify
changes in functional connectivity.
5. Magnetic resonance spectroscopy to depict themechanisms of
neurodegeneration, such as involvement of energymetabolism
due to mitochondrial dysfunction, which may be subject to
faster change than other aspects of MR-based imaging (e.g.,
changes in gray matter).
Metabolic Studies
To investigate whether metabolic changes in LRRK2 carriers
already exist before the motor manifestation or are secondary to
it, we conduct the following studies:
1. Energy consumption at rest using indirect calorimetry, where
energy consumption is determined by measuring the air the
subject breathes.
2. Measurement of body composition, i.e., the proportion of
body fat mass and lean mass, employing air displacement
plethysmography. In addition, body circumference (e.g., waist
and hips) and body skin folds (e.g., on the arm and waist)
are measured.
3. Measurement of physical activity and sleep behavior
under everyday conditions using accelerometry. The study
participants are asked to wear the accelerometer in the form
of a wristwatch continuously for 7 days.
Genome-Wide Association Study Analysis
We will perform a genome-wide association study analysis in
manifesting vs. non-manifesting carriers aimed at discovering
genetic modifiers of penetrance of LRRK2 pathogenic variants.
Toxicological Analyses of Household Dust
A broad non-target liquid chromatography high-resolution mass
spectrometry (LC-HR-MS) screening will be performed on
household dust samples collected by participants in vacuum bags
[see (10)], with identification of potential toxicants of interest
via the in silico fragmenter MetFrag (11) coupled with open
chemical databases such as PubChem (12) and CompTox (13),
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TABLE 1 | Content of the LIPAD electronic case report form.
Demographic and
general data
Genetic result, age, gender, years of education, the
highest level of education, handedness,
medication/treatment, medical history, family history
concerning PD
PD criteria MDS clinical diagnostic criteria for PD, absolute
exclusion criteria, red flags
Clinical scores MDS-UPDRS (Movement Disorder Society – Unified
Parkinson’s Disease Rating Scale)
Hoehn & Yahr scale
Schwab & England scale
Brief smell identification test (BSIT)
Montreal Cognitive Assessment (MoCA)
The self-rating part PD risk factor questionnaire (PD-RFQ-U)
Food frequency questionnaire
Autonomic dysfunction (SCOPA-AUT)
WHO Quality of life questionnaire (WHO-QoL)
Pittsburgh Sleep Quality Inventory
Epworth Sleepiness Scale
Hospital Anxiety and Depression Scales
plus specific neurotoxicity-related candidate lists and end-point
information (14).
RESULTS
A comprehensive eCRF has been developed, consisting of
an investigator-rated (1 h) and a self-rated (1.5-h) part. The
questionnaires are listed in Table 1. We used validated versions
of questionnaires and scales in the local languages.
The first 10 centers across Germany and five international sites
have been initiated with further centers currently undergoing
ethical review (Figure 2). The first 150 participants have been
enrolled (as of March 25th, 2021); Table 2.
DISCUSSION
LIPAD is a large-scale international scientific effort focusing on
deep phenotyping of LRRK2-linked PD and healthy pathogenic
variant carriers, including a comparison with additional relatively
frequent genetic forms of PD, and with a future perspective
to identify genetic and environmental modifiers of penetrance
and expressivity.
The clinical assessment in LIPAD is close to the one used in
the currently largest multinational cohort of genetic PD (PPMI),
except for lack of collection of cerebrospinal fluid, but with the
addition of an extensive questionnaire on environmental factors
(15). Further, there are no restrictions on the age at diagnosis
or medication for inclusion in the LIPAD study. Several other
multinational prospective studies focusing on pathogenic LRRK2
variants included only a small number of populations (4, 16,
17), revealing an important knowledge gap in multinational,
standardized, genetic prospective studies, which LIPAD is aiming
to close.
A comprehensive investigation of modifiers of penetrance
and expressivity requires assessment of a considerable number
of pathogenic variant carriers. Due to the direct enrolment
of family members at an international scale, the LIPAD study
will enable the analysis of modifiers of penetrance in different
populations in one setting. Our recruitment strategy, mainly
through the international multicenter ROPAD study, will ensure
participation of a large number of LRRK2+/PD+ patients.
With the nested studies, which will be conducted on a subset
of participants, we are aiming to provide a more in-depth
phenotypic characterization especially of non-affected carriers of
LRRK2 pathogenic variants.
Currently, a complication affecting many patient studies
across the world are measures imposed on personal visits to
contain SARS-CoV-2 in many countries, limiting the possibility
for the collection of data and biomaterials. To allow the study
to proceed under these circumstances, we adjusted the protocol
and procedures to collect the necessary data online. After making
an online appointment, patients receive a package with patient
information, informed consent forms, and a smell test by post.
Then an online appointment with the study team takes place,
during which the study is explained, the data is collected and
the examination is performed. Study participants send signed
informed consent forms and a household dust sample back to
the study center by post. Biomaterials will be taken at a general
practitioner’s office or the study center at a later time point
when study visits become possible again. The study will revert
to the on-site recruitment as soon as possible after the pandemic
restrictions are lifted.
LIPAD aims for a longitudinal follow-up of its study
participants over a 10–15-year time period. The exact protocol
is currently being developed and potential funding opportunities
are being explored.
ETHICS STATEMENT
The studies involving human participants were reviewed
and approved by Ethics Committee (EC) of the University
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FIGURE 2 | International centers participating in LIPAD. In blue: centers with ethics approval; in black: centers in the process of receiving ethics approval.
TABLE 2 | Exemplary demographic and clinical characteristics of the first 150 enrolled LIPAD participants.
LRRK2+/PD+ (group 1) LRRK2+/PD-(group 2) iPD;LRRK-/ PD+ (group 3) genPD (group 4) HC (group 5)
N = 7 N = 1 N = 115 N = 25 N = 2
Sex (male), n (%) 2 (28.6%) 0 64 (55.7%) 15 (60%) 2 (100%)
Age, mean (±SD) 60.6 (± 9.2) 40 63.3 (± 10.8) 56.4 (± 11.6) 57 (± 12)
Family history of PD,
n (%)
3 (42.9%) 1 (100%) 19 (16.5%) 7 (28%) 1 (50%)
MDS-UPDRSIII, mean 37.7 (± 20.3) 0 34.3 (± 14.4) 28.6 (± 12.5) 4 (± 4)
(±SD), n complete N = 3 N = 1 N = 59 N = 11 N = 2
H&Y, mean (±SD) 3 (± 0.6) 0 2.1 (± 0.6) 2.1 (± 0.7) 0.5 (± 0.5)
Schwab & England
Scale, mean (±SD)
71.7 (± 21.1) - 81.9 (± 14.7) 84.4 (± 11.2) 100 (± 0)
MoCA, mean (±SD) 25.8 (± 3.3) 29 26.6 (± 3.3) 27.6 (± 2.1) 26.5 (± 1.5)
BSIT, mean (±SD) 6.2 (± 1.7) 11 6 (± 2.6) 6.5 (± 3.3) 11 (± 1)
H&Y, Hoehn and Yahr; MoCA, Montreal Cognitive Assessment; BSIT, Brief Smell Identification Test.
de Valdecilla, Santander, Spain; Stuart Isaacson, Parkinson’s
Disease and Movement Disorder Center of Boca Raton, Boca
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